Pancreatic cancer
Anocca secures £32m to advance pancreatic cancer trial
August 18, 2025Research and Development Anocca, Oncology, Pancreatic cancer, research funding
Swedish biopharma Anocca has raised approximately £32m (SEK 440m) to support the early-stage clinical development of VIDAR-1, its lead TCR-T …
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
April 15, 2024Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment
January 18, 2024Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial
Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …
Jacobio Pharma receives CDE approval for pancreatic cancer study in China
July 5, 2023Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial
Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved by …
Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins
May 18, 2023Research and Development Aitia, Digital Twins, Oncology, Pancreatic cancer, Servier
French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced a collaboration to create Digital …
Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer
June 1, 2020Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza
Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …
Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer
February 19, 2020Research and Development Bristol-Myers Squibb, Five Prime Therapeutics, Pancreatic cancer, cabiralizumab, opdivo, pharma
Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s …
FDA advisory committee approves the use of Lynparza in pancreatic cancer
December 18, 2019Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …
Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer
October 17, 2019Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma
In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …
Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show
April 3, 2019Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma
At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …
Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer
February 26, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma
AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …
NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment
August 4, 2017Medical Communications, Sales and Marketing Cancer, Celgene, NICE, Pancreatic cancer, drugs, healthcare, life sciences, medicine, pharma, pharmaceuticals
Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination …
UK underperforming in cancer care compared to Europe, according to ABPI report
July 18, 2017Research and Development ABPI, Cancer, Pancreatic cancer, biotech, heralthcare, lung cancer, ovarian cancer, pharma, pharmaceutical
According to a new report commissioned by the ABPI, the UK is continuing to fall behind in the diagnosis and …
NICE turns down Shire’s pancreatic cancer treatment
April 4, 2017Manufacturing and Production, Sales and Marketing NICE, Pancreatic cancer, Shire
NICE has announced its intention not to recommend the NHS use of Shire’s Onivyde (pegylated liposomal irinotecan) for the treatment …
Cancer Research UK announces £10m pancreatic cancer project
March 24, 2017Medical Communications, Research and Development Cancer Research UK, Pancreatic cancer
Cancer Research UK has revealed a £10 million investment into PRECISION-Panc, a pancreatic cancer-focused project which aims to improve patient …
